Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations

被引:6
作者
Kim, In Ae [1 ]
Hur, Jae Young [1 ,2 ]
Kim, Hee Joung [1 ,3 ]
Lee, Song Am [4 ]
Hwang, Jae Joon [4 ]
Kim, Wan Seop [1 ,2 ]
Lee, Kye Young [1 ]
机构
[1] Konkuk Univ, Med Ctr, Precis Med Lung Canc Ctr, Seoul 05030, South Korea
[2] Konkuk Univ, Sch Med, Dept Pathol, Seoul 05030, South Korea
[3] Konkuk Univ, Sch Med, Dept Pulm Med, Seoul 05030, South Korea
[4] Konkuk Univ, Sch Med, Dept Thorac Surg, Seoul 05030, South Korea
关键词
targeted next-generation sequencing; resected EGFR mutated-lung adenocarcinoma; CTNNB1; post-operative recurrence; recurrence-free survival; STAGE-I; RISK-FACTORS; TUMOR RECURRENCE; TP53; MUTATIONS; CANCER; IMPACT; CLASSIFICATION; SURVIVAL; EDITION;
D O I
10.3390/cancers13143632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Despite complete resection and adjuvant chemotherapy, the recurrence rate of early EGFR-mutated lung adenocarcinoma remains high. We hypothesized that patients with recurrence-related genetic alterations would have poor prognosis and analyzed the genetic profiles of 131 patients using next-generation sequencing (NGS) with a 207 cancer-related gene panel. As a result, we revealed several negative prognostic factors for recurrence, such as a large number of concomitant mutations and the existence of specific mutation subtypes. Targeted NGS analysis provides information on the prognosis of patients with resected EGFR-mutation lung adenocarcinoma and helps to identify patients with high relapse risks who require intensive chemotherapy or adjuvant EGFR-TKIs treatments. Targeted NGS, widely applied to identify driver oncogenes in advanced lung adenocarcinoma, may also be applied to resected early stage cancers. We investigated resected EGFR-mutated lung adenocarcinoma mutation profiles to evaluate prognostic impacts. Tissues from 131 patients who had complete resection of stage I-IIIA EGFR-mutated lung adenocarcinoma were analyzed by targeted NGS for 207 cancer-related genes. Recurrence free survival (RFS) was estimated according to genetic alterations using the Kaplan-Meier method and Cox proportional regression analysis. The relapse rate was 25.2% (33/131). Five-year RFS of stages IA, IB, II, and IIIA were 82%, 75%, 35%, and 0%, respectively (p < 0.001). RFS decreased with the number of co-mutations (p = 0.025). Among co-mutations, the CTNNB1 mutation was associated with short RFS in a multivariate analysis (hazard ratio: 5.4, 95% confidence interval: 2.1-14.4; p = 0.001). TP53 mutations were associated with short RFS in stage IB-IIIA (p = 0.01). RFS was shorter with EGFR exon 19 deletion (19-del) than with mutation 21-L858R in stage IB-IIIA tumors (p = 0.008). Among 19-del subtypes, pL747_P753delinS (6/56, 8.9%) had shorter RFS than pE746_A750del (39/56, 69.6%), the most frequent subtype (p = 0.004).
引用
收藏
页数:14
相关论文
共 40 条
[1]   The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2) [J].
Aisner, Dara L. ;
Sholl, Lynette M. ;
Berry, Lynne D. ;
Rossi, Michael R. ;
Chen, Heidi ;
Fujimoto, Junya ;
Moreira, Andre L. ;
Ramalingam, Suresh S. ;
Villaruz, Liza C. ;
Otterson, Gregory A. ;
Haura, Eric ;
Politi, Katerina ;
Glisson, Bonnie ;
Cetnar, Jeremy ;
Garon, Edward B. ;
Schiller, Joan ;
Waqar, Saiama N. ;
Sequist, Lecia V. ;
Brahmer, Julie ;
Shyr, Yu ;
Kugler, Kelly ;
Wistuba, Ignacio I. ;
Johnson, Bruce E. ;
Minna, John D. ;
Kris, Mark G. ;
Bunn, Paul A. ;
Kwiatkowski, David J. .
CLINICAL CANCER RESEARCH, 2018, 24 (05) :1038-1047
[2]   Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer [J].
Chen, Minjiang ;
Xu, Yan ;
Zhao, Jing ;
Zhong, Wei ;
Zhang, Li ;
Bi, Yalan ;
Wang, Mengzhao .
EBIOMEDICINE, 2019, 42 :304-310
[3]   A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer [J].
Cheng, Hua ;
Li, Xiao-Jian ;
Wang, Xiao-Jin ;
Chen, Zuo-Wen ;
Wang, Rui-Qi ;
Zhong, Hong-Cheng ;
Wu, Tian-Chi ;
Cao, Qing-Dong .
LUNG CANCER, 2019, 137 :7-13
[4]  
Cho William C S, 2018, Oncotarget, V9, P36344, DOI 10.18632/oncotarget.26349
[5]   Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing [J].
Chun, You Jin ;
Choi, Jae Woo ;
Hong, Min Hee ;
Jung, Dongmin ;
Son, Hyeonju ;
Cho, Eun Kyung ;
Min, Young Joo ;
Kim, Sang-We ;
Park, Keunchil ;
Lee, Sung Sook ;
Kim, Sangwoo ;
Kim, Hye Ryun ;
Cho, Byoung Chul .
PLOS ONE, 2019, 14 (11)
[6]   Comprehensive molecular profiling of lung adenocarcinoma [J].
Collisson, Eric A. ;
Campbell, Joshua D. ;
Brooks, Angela N. ;
Berger, Alice H. ;
Lee, William ;
Chmielecki, Juliann ;
Beer, David G. ;
Cope, Leslie ;
Creighton, Chad J. ;
Danilova, Ludmila ;
Ding, Li ;
Getz, Gad ;
Hammerman, Peter S. ;
Hayes, D. Neil ;
Hernandez, Bryan ;
Herman, James G. ;
Heymach, John V. ;
Jurisica, Igor ;
Kucherlapati, Raju ;
Kwiatkowski, David ;
Ladanyi, Marc ;
Robertson, Gordon ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Sinha, Rileen ;
Sougnez, Carrie ;
Tsao, Ming-Sound ;
Travis, William D. ;
Weinstein, John N. ;
Wigle, Dennis A. ;
Wilkerson, Matthew D. ;
Chu, Andy ;
Cherniack, Andrew D. ;
Hadjipanayis, Angela ;
Rosenberg, Mara ;
Weisenberger, Daniel J. ;
Laird, Peter W. ;
Radenbaugh, Amie ;
Ma, Singer ;
Stuart, Joshua M. ;
Byers, Lauren Averett ;
Baylin, Stephen B. ;
Govindan, Ramaswamy ;
Meyerson, Matthew ;
Rosenberg, Mara ;
Gabriel, Stacey B. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Kim, Jaegil ;
Stewart, Chip .
NATURE, 2014, 511 (7511) :543-550
[7]   Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib [J].
D'Angelo, Sandra P. ;
Janjigian, Yelena Y. ;
Ahye, Nicholas ;
Riely, Gregory J. ;
Chaft, Jamie E. ;
Sima, Camelia S. ;
Shen, Ronglai ;
Zheng, Junting ;
Dycoco, Joseph ;
Kris, Mark G. ;
Zakowski, Maureen F. ;
Ladanyi, Marc ;
Rusch, Valerie ;
Azzoli, Christopher G. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) :1815-1822
[8]   Recurrence Dynamics for Non-Small-Cell Lung Cancer Effect of Surgery on the Development of Metastases [J].
Demicheli, Romano ;
Fornili, Marco ;
Ambrogi, Federico ;
Higgins, Kristin ;
Boyd, Jessamy A. ;
Biganzoli, Elia ;
Kelsey, Chris R. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (04) :723-730
[9]   Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer [J].
Dziedzic, Dariusz Adam ;
Rudzinski, Piotr ;
Langfort, Renata ;
Orlowski, Tadeusz .
CLINICAL LUNG CANCER, 2016, 17 (05) :E157-E167
[10]   The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].
Goldstraw, Peter ;
Chansky, Kari ;
Crowley, John ;
Rami-Porta, Ramon ;
Asamura, Hisao ;
Eberhardt, Wilfried E. E. ;
Nicholson, Andrew G. ;
Groome, Patti ;
Mitchell, Alan ;
Bolejack, Vanessa .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51